Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses: 2015-2024

Historic Change in Accured Expenses for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Dec 2024 value amounting to $21.9 million.

  • Rhythm Pharmaceuticals' Change in Accured Expenses rose 46.71% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 208.84%. This contributed to the annual value of $21.9 million for FY2024, which is 48.37% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Change in Accured Expenses of $21.9 million as of FY2024, which was up 48.37% from $14.8 million recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Change in Accured Expenses ranged from a high of $21.9 million in FY2024 and a low of -$6.4 million during FY2020.
  • Its 3-year average for Change in Accured Expenses is $12.7 million, with a median of $14.8 million in 2023.
  • In the last 5 years, Rhythm Pharmaceuticals' Change in Accured Expenses slumped by 161.35% in 2020 and then soared by 857.42% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Change in Accured Expenses (Yearly) stood at -$6.4 million in 2020, then spiked by 384.08% to $18.3 million in 2021, then tumbled by 91.57% to $1.5 million in 2022, then soared by 857.42% to $14.8 million in 2023, then spiked by 48.37% to $21.9 million in 2024.